🔎 Trials Near Me

Beranda › Glioblastoma › Illinois

Uji klinis Glioblastoma di Illinois

16 studi untuk Glioblastoma mencari peserta di lokasi di Illinois.

Kota di Illinois

Teks studi resmi (Bahasa Inggris)

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

  • University of Chicago Comprehensive Cancer Center, Chicago
  • University of Chicago Medicine-Orland Park, Orland Park
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT05432804

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

  • Northwestern University, Chicago
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT05902169

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

  • Northwestern Univerity, Chicago
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05303467

Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma

  • Alton Memorial Hospital, Alton
  • Decatur Memorial Hospital, Decatur
  • Northwestern Medicine Cancer Center Kishwaukee, DeKalb
  • dan 5 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT07452458

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

  • Northwestern University, Chicago
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06410248

Targeted Pediatric High-Grade Glioma Therapy

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Menerima pesertaStudi observasional
12 Months – 39 Years · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT05839379

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

  • Northwestern University, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT06860594

Study of Olutasidenib and Temozolomide in HGG

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Menerima pesertaFase 2
Usia 12 hingga 39 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT06161974

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

  • University of Chicago, Chicago
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT05303519

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

  • Northwestern Medicine, Chicago
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT07464925

WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

  • Northwestern University, Chicago
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT05879250

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Menerima pesertaFase awal 1Sukarelawan sehat diterima
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT06333899

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Menerima pesertaFase 2
12 Months – 39 Years · Semua jenis kelamin · Diperbarui 29 Mei 2026 · NCT05843253

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

  • Northwestern Memorial Hospital, Chicago
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Apr 2026 · NCT06810544

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Chicago
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.